What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...